| Title: |
Prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study) |
| Authors: |
Bonnot, P; Lintis, A; Mercier, F; Benzerdjeb, N; Passot, G; Pocard, M; Meunier, B; Bereder, J; Abboud, K; Marchal, F; Quenet, F; Goere, D; Msika, S; Arvieux, C; Pirro, N; Wernert, R; Rat, P; Gagnière, J; Lefevre, J; Courvoisier, T; Kianmanesh, R; Vaudoyer, D; Rivoire, M; Meeus, P; Villeneuve, L; Piessen, G; Glehen, O; Abba, Julio; Alyami, Mohammad; Bakrin, Naoual; Bernard, Jean-Louis; Bibeau, F; Bouzard, Dominique; Brigand, C; Carrère, Sébastien; Carretier, Michel; Castel, Benjamin; Cotte, Eddy; Celerier, Bertrand; Ceribelli, Cécilia; de Chaisemartin, Cécile; de Franco, Valeria; Deguelte-Lardiere, Sophie; Delpero, Jean-Robert; Desolneux, Grégoire; Dumont, Frédéric; Eveno, Clarisse; Durand-Fontanier, Sylvaine; Evrard, Serge; Facy, Olivier; Gelli, Maximiliano; Gilly, François-Noël; Guilloit, Jean-Marc; Heyd,, Bruno; Lelong, Bernard; Lo Dico, Réa; Loi, Valeria; Mariani, Pascale; Meffert, Jean-Luc; Ortega-Deballon, Pablo; Paquette, Brice; Petorin, Caroline; Passot, Guillaume; Peyrat, Patrice; Pezet, Denis; Regimbeau, Jean-Marc; Rohr, Serge; Sabbagh, Charles; Seitz, Jean-François; Sgarbura, Olivia; Sielezneff, Igor; Sourrouille, Isabelle; Taibi, Abdelkader; Thibaudeau, Emilie; Tuech, Jean-Jacques; Vanbockstael, Julie |
| Contributors: |
Centre pour l'innovation en cancérologie de Lyon (CICLY); Université Claude Bernard Lyon 1 (UCBL); Université de Lyon-Université de Lyon; Hospices Civils de Lyon (HCL); Université de Lyon; Hôpital Lariboisière-Fernand-Widal APHP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); CArcinose Péritoine Paris-Technologies (ex-CART) (CAP Paris-Tech (UMR_S_1275)); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité); Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Pontchaillou; Centre Hospitalier Universitaire de Saint-Etienne CHU Saint-Etienne (CHU ST-E); Institut de Cancérologie de Lorraine - Alexis Vautrin Nancy (UNICANCER/ICL); UNICANCER; Institut régional de Cancérologie de Montpellier (ICM); Centre de recherche en épidémiologie et santé des populations (CESP); Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse; AP-HP. Université Paris Saclay-AP-HP. Université Paris Saclay-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay; Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)); Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité); AP-HP - Hôpital Bichat - Claude Bernard Paris; University Hospital Grenoble-Alpes, BP 217, 38043 Grenoble Cedex 9, France. 8; Hôpital de la Timone CHU - APHM (TIMONE); Service de Chirurgie Digestive, Cancérologique, Générale, Endocrinienne et Urgences (CHU de Dijon); Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon); CHU Gabriel Montpied Clermont-Ferrand; CHU Clermont-Ferrand; CHU Saint-Antoine AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU); Sorbonne Université - Faculté de Médecine (SU FM); Sorbonne Université (SU); Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 (CANTHER); Institut Pasteur de Lille; Pasteur Network (Réseau International des Instituts Pasteur)-Pasteur Network (Réseau International des Instituts Pasteur)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS); Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille) |
| Source: |
ISSN: 0007-1323. |
| Publisher Information: |
CCSD; Wiley |
| Publication Year: |
2021 |
| Collection: |
Université de Versailles Saint-Quentin-en-Yvelines: HAL-UVSQ |
| Subject Terms: |
[SDV.CAN]Life Sciences [q-bio]/Cancer |
| Description: |
International audience ; Abstract Background The incidence of gastric poorly cohesive carcinoma (PCC) is increasing. The prognosis for patients with peritoneal metastases remains poor and the role of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is controversial. The aim was to clarify the impact of gastric PCC with peritoneal metastases treated by CRS with or without HIPEC. Methods All patients with peritoneal metastases from gastric cancer treated with CRS with or without HIPEC, in 19 French centres, between 1989 and 2014, were identified from institutional databases. Clinicopathological characteristics and outcomes were compared between PCC and non-PCC subtypes, and the possible benefit of HIPEC was assessed. Results In total, 277 patients were included (188 PCC, 89 non-PCC). HIPEC was performed in 180 of 277 patients (65 per cent), including 124 of 188 with PCC (66 per cent). Median overall survival (OS) was 14.7 (95 per cent c.i. 12.7 to 17.3) months in the PCC group versus 21.2 (14.7 to 36.4) months in the non-PCC group (P < 0.001). In multivariable analyses, PCC (hazard ratio (HR) 1.51, 95 per cent c.i. 1.01 to 2.25; P = 0.044) was associated with poorer OS, as were pN3, Peritoneal Cancer Index (PCI), and resection with a completeness of cytoreduction score of 1, whereas HIPEC was associated with improved OS (HR 0.52; P < 0.001). The benefit of CRS-HIPEC over CRS alone was consistent, irrespective of histology, with a median OS of 16.7 versus 11.3 months (HR 0.60, 0.39 to 0.92; P = 0.018) in the PCC group, and 34.5 versus 14.3 months (HR 0.43, 0.25 to 0.75; P = 0.003) in the non-PCC group. Non-PCC and HIPEC were independently associated with improved recurrence-free survival and fewer peritoneal recurrences. In patients who underwent HIPEC, PCI values of below 7 and less than 13 were predictive of OS in PCC and non-PCC populations respectively. Conclusion In selected patients, CRS-HIPEC offers acceptable outcomes among those with gastric PCC and long survival for ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/bjs/znab200 |
| Availability: |
https://hal.science/hal-04522436; https://doi.org/10.1093/bjs/znab200 |
| Accession Number: |
edsbas.42D7AB72 |
| Database: |
BASE |